Product Code: A17522
Huntington's disease is a rare, genetic condition that results in progressive destruction of brain nerve cells. The rate at which symptoms appear can differ from person to person. For some people, motor skill changes come first, followed by depressive symptoms. Changes in mood and strange behavior are frequent early warning indicators. Functional capacities of a person are significantly impacted by Huntington's disease, which typically causes mobility, cognitive, and psychological issues. Medications are available to help manage symptoms of Huntington's disease. There is currently no authorized disease-modifying medication for patients with Huntington's disease.
Major factors that drive growth of the Huntington's disease treatment market is increase in prevalence population and rise in demand for advanced drug types for controlling symptoms associated with Huntington's. In addition, strong drug type pipeline is a key trend in the market, which is expected to fuel growth during the forecast period.
Significant surge in patient population is one of the leading factors in the market as rise in patient lead to increase in demand for drugs. For instance, according to a research paper published by BJM Journal, there is high prevalence of HD in the UK. Such high prevalence of HD requires more ingenuity and responsiveness in its care. Thus, such high number of cases are expected to boost the Huntington's disease treatment market growth.
In addition, surge in demand for advanced treatment such as gene therapy and stem cell therapy in the past decade drives the market growth. Furthermore, rise in R&D investments in drug discovery and development serves as an lucrative opportunity for the market growth. However, complications associated with drug development process expected to hamper the market growth.
The global Huntington's disease treatment market is segmented on the basis of drug type, age, distribution channel, and region. On the basis of drug type, the market is categorized into approved drugs and off-label drugs. The approved drug segment is further classified into tetrabenazine and deutetrabenazine. By age, the market is divided into below 50 years and above 50 years. By distribution channel, it is segmented into hospital pharmacies, drug store & retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).
Major players profiled in the report are Annexon Biosciences, Bausch Health Companies Inc, Dr.Reddy's Laboratories Ltd, Eli Lilly And Company, Hikma Pharmaceuticals PLC, Lupin, Medesis pharma SA, Mitochon Pharmaceuticals, Neurocrine bioscience Inc., Novartis, PTC Therapeutics, Inc, SOM Biotech, Sun Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., UniQure, and Vaccinex, Inc.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the huntington's disease treatment market analysis from 2021 to 2031 to identify the prevailing huntington's disease treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the huntington's disease treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global huntington's disease treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug type
- Approved drugs
- Type
- Tetrabenazine
- Deutetrabenazine
- Offlabel drugs
By Age
- Below 50 years
- Above 50 years
By Distribution channel
- Hospital pharmacies
- Drug store and retail pharmacies
- Online pharmacies
By Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest Of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest Of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest Of LAMEA
- Key Market Players
- Prilenia Therapeutics
- som biotech
- Bausch Health Companies Inc.
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Lupin
- UniQure
- Hikma Pharmaceuticals plc
- Annexon Biosciences
- Dr. Reddy's Laboratories Ltd.
- Neurocrine Biosciences
- PTC Therapeutics
- AOP Health
- Medesis Pharma SA
- Mitochon Pharmaceuticals
- Sun Pharmaceuticals Industries Ltd.
- Vaccinex, Inc
TABLE OF CONTENTS
CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter's five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Approved drugs
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market share analysis by country
- 4.2.4 Approved drugs Huntington's Disease Treatment Market by Type
- 4.2.4.1 Tetrabenazine Market size and forecast, by region
- 4.2.4.2 Deutetrabenazine Market size and forecast, by region
- 4.3 Offlabel drugs
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market share analysis by country
CHAPTER 5: HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Below 50 years
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market share analysis by country
- 5.3 Above 50 years
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market share analysis by country
CHAPTER 6: HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Hospital pharmacies
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market share analysis by country
- 6.3 Drug store and retail pharmacies
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market share analysis by country
- 6.4 Online pharmacies
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market share analysis by country
CHAPTER 7: HUNTINGTON'S DISEASE TREATMENT MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Drug type
- 7.2.2.1 North America Approved drugs Huntington's Disease Treatment Market by Type
- 7.2.3 North America Market size and forecast, by Age
- 7.2.4 North America Market size and forecast, by Distribution channel
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Key market trends, growth factors and opportunities
- 7.2.5.1.2 Market size and forecast, by Drug type
- 7.2.5.1.3 Market size and forecast, by Age
- 7.2.5.1.4 Market size and forecast, by Distribution channel
- 7.2.5.2 Canada
- 7.2.5.2.1 Key market trends, growth factors and opportunities
- 7.2.5.2.2 Market size and forecast, by Drug type
- 7.2.5.2.3 Market size and forecast, by Age
- 7.2.5.2.4 Market size and forecast, by Distribution channel
- 7.2.5.3 Mexico
- 7.2.5.3.1 Key market trends, growth factors and opportunities
- 7.2.5.3.2 Market size and forecast, by Drug type
- 7.2.5.3.3 Market size and forecast, by Age
- 7.2.5.3.4 Market size and forecast, by Distribution channel
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Drug type
- 7.3.2.1 Europe Approved drugs Huntington's Disease Treatment Market by Type
- 7.3.3 Europe Market size and forecast, by Age
- 7.3.4 Europe Market size and forecast, by Distribution channel
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Key market trends, growth factors and opportunities
- 7.3.5.1.2 Market size and forecast, by Drug type
- 7.3.5.1.3 Market size and forecast, by Age
- 7.3.5.1.4 Market size and forecast, by Distribution channel
- 7.3.5.2 France
- 7.3.5.2.1 Key market trends, growth factors and opportunities
- 7.3.5.2.2 Market size and forecast, by Drug type
- 7.3.5.2.3 Market size and forecast, by Age
- 7.3.5.2.4 Market size and forecast, by Distribution channel
- 7.3.5.3 UK
- 7.3.5.3.1 Key market trends, growth factors and opportunities
- 7.3.5.3.2 Market size and forecast, by Drug type
- 7.3.5.3.3 Market size and forecast, by Age
- 7.3.5.3.4 Market size and forecast, by Distribution channel
- 7.3.5.4 Italy
- 7.3.5.4.1 Key market trends, growth factors and opportunities
- 7.3.5.4.2 Market size and forecast, by Drug type
- 7.3.5.4.3 Market size and forecast, by Age
- 7.3.5.4.4 Market size and forecast, by Distribution channel
- 7.3.5.5 Spain
- 7.3.5.5.1 Key market trends, growth factors and opportunities
- 7.3.5.5.2 Market size and forecast, by Drug type
- 7.3.5.5.3 Market size and forecast, by Age
- 7.3.5.5.4 Market size and forecast, by Distribution channel
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Key market trends, growth factors and opportunities
- 7.3.5.6.2 Market size and forecast, by Drug type
- 7.3.5.6.3 Market size and forecast, by Age
- 7.3.5.6.4 Market size and forecast, by Distribution channel
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Drug type
- 7.4.2.1 Asia-Pacific Approved drugs Huntington's Disease Treatment Market by Type
- 7.4.3 Asia-Pacific Market size and forecast, by Age
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution channel
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Key market trends, growth factors and opportunities
- 7.4.5.1.2 Market size and forecast, by Drug type
- 7.4.5.1.3 Market size and forecast, by Age
- 7.4.5.1.4 Market size and forecast, by Distribution channel
- 7.4.5.2 China
- 7.4.5.2.1 Key market trends, growth factors and opportunities
- 7.4.5.2.2 Market size and forecast, by Drug type
- 7.4.5.2.3 Market size and forecast, by Age
- 7.4.5.2.4 Market size and forecast, by Distribution channel
- 7.4.5.3 India
- 7.4.5.3.1 Key market trends, growth factors and opportunities
- 7.4.5.3.2 Market size and forecast, by Drug type
- 7.4.5.3.3 Market size and forecast, by Age
- 7.4.5.3.4 Market size and forecast, by Distribution channel
- 7.4.5.4 Australia
- 7.4.5.4.1 Key market trends, growth factors and opportunities
- 7.4.5.4.2 Market size and forecast, by Drug type
- 7.4.5.4.3 Market size and forecast, by Age
- 7.4.5.4.4 Market size and forecast, by Distribution channel
- 7.4.5.5 South Korea
- 7.4.5.5.1 Key market trends, growth factors and opportunities
- 7.4.5.5.2 Market size and forecast, by Drug type
- 7.4.5.5.3 Market size and forecast, by Age
- 7.4.5.5.4 Market size and forecast, by Distribution channel
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Key market trends, growth factors and opportunities
- 7.4.5.6.2 Market size and forecast, by Drug type
- 7.4.5.6.3 Market size and forecast, by Age
- 7.4.5.6.4 Market size and forecast, by Distribution channel
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Drug type
- 7.5.2.1 LAMEA Approved drugs Huntington's Disease Treatment Market by Type
- 7.5.3 LAMEA Market size and forecast, by Age
- 7.5.4 LAMEA Market size and forecast, by Distribution channel
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Key market trends, growth factors and opportunities
- 7.5.5.1.2 Market size and forecast, by Drug type
- 7.5.5.1.3 Market size and forecast, by Age
- 7.5.5.1.4 Market size and forecast, by Distribution channel
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Key market trends, growth factors and opportunities
- 7.5.5.2.2 Market size and forecast, by Drug type
- 7.5.5.2.3 Market size and forecast, by Age
- 7.5.5.2.4 Market size and forecast, by Distribution channel
- 7.5.5.3 South Africa
- 7.5.5.3.1 Key market trends, growth factors and opportunities
- 7.5.5.3.2 Market size and forecast, by Drug type
- 7.5.5.3.3 Market size and forecast, by Age
- 7.5.5.3.4 Market size and forecast, by Distribution channel
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Key market trends, growth factors and opportunities
- 7.5.5.4.2 Market size and forecast, by Drug type
- 7.5.5.4.3 Market size and forecast, by Age
- 7.5.5.4.4 Market size and forecast, by Distribution channel
CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
CHAPTER 9: COMPANY PROFILES
- 9.1 Prilenia Therapeutics
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 som biotech
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Bausch Health Companies Inc.
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Teva Pharmaceutical Industries Ltd.
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Novartis AG
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Lupin
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 UniQure
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Hikma Pharmaceuticals plc
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Annexon Biosciences
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Dr. Reddy's Laboratories Ltd.
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- 9.11 Neurocrine Biosciences
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
- 9.12 PTC Therapeutics
- 9.12.1 Company overview
- 9.12.2 Company snapshot
- 9.12.3 Operating business segments
- 9.12.4 Product portfolio
- 9.12.5 Business performance
- 9.12.6 Key strategic moves and developments
- 9.13 AOP Health
- 9.13.1 Company overview
- 9.13.2 Company snapshot
- 9.13.3 Operating business segments
- 9.13.4 Product portfolio
- 9.13.5 Business performance
- 9.13.6 Key strategic moves and developments
- 9.14 Medesis Pharma SA
- 9.14.1 Company overview
- 9.14.2 Company snapshot
- 9.14.3 Operating business segments
- 9.14.4 Product portfolio
- 9.14.5 Business performance
- 9.14.6 Key strategic moves and developments
- 9.15 Mitochon Pharmaceuticals
- 9.15.1 Company overview
- 9.15.2 Company snapshot
- 9.15.3 Operating business segments
- 9.15.4 Product portfolio
- 9.15.5 Business performance
- 9.15.6 Key strategic moves and developments
- 9.16 Sun Pharmaceuticals Industries Ltd.
- 9.16.1 Company overview
- 9.16.2 Company snapshot
- 9.16.3 Operating business segments
- 9.16.4 Product portfolio
- 9.16.5 Business performance
- 9.16.6 Key strategic moves and developments
- 9.17 Vaccinex, Inc
- 9.17.1 Company overview
- 9.17.2 Company snapshot
- 9.17.3 Operating business segments
- 9.17.4 Product portfolio
- 9.17.5 Business performance
- 9.17.6 Key strategic moves and developments